{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:58:11Z","timestamp":1792033091278,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T00:00:00Z","timestamp":1733616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comprehensive Psychiatry"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.comppsych.2024.152566","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T19:00:54Z","timestamp":1733857254000},"page":"152566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Pharmacological management of gambling disorder: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"137","author":[{"given":"Konstantinos","family":"Ioannidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Del Giovane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charidimos","family":"Tzagarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy E.","family":"Solly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Westwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Parlatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrietta","family":"Bowden-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon E.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel R.","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.comppsych.2024.152566_bb0005","article-title":"Gambling: a neglected public health issue","volume":"6","author":"The Lancet Public Health","year":"2021","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.comppsych.2024.152566_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2019.109852","article-title":"Gambling and substance use: Comorbidity and treatment implications","volume":"99","author":"Grant","year":"2020","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatr"},{"key":"10.1016\/j.comppsych.2024.152566_bb0015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S2215-0366(21)00356-4","article-title":"Gambling Disorder in the United Kingdom: key research priorities and the urgent need for independent research funding","volume":"9","author":"Bowden-Jones","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152566_bb0020","series-title":"ICD-11 for Mortality and Morbidity Statistics","author":"ICD-11","year":"2021"},{"key":"10.1016\/j.comppsych.2024.152566_bb0025","series-title":"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). Diagnostic Stat Man Ment Disord","author":"American Psychiatric Association","year":"2022"},{"key":"10.1016\/j.comppsych.2024.152566_bb0030","first-page":"1","article-title":"Rapid evidence review of the evidence-based treratment for Gambling disorder in Britain","author":"Bowden-Jones","year":"2016","journal-title":"RCPsych"},{"key":"10.1016\/j.comppsych.2024.152566_bb0035","doi-asserted-by":"crossref","first-page":"664","DOI":"10.5694\/mja11.11088","article-title":"Australian guideline for treatment of problem gambling: an abridged outline","volume":"195","author":"Thomas","year":"2011","journal-title":"Med J Aust"},{"key":"10.1016\/j.comppsych.2024.152566_bb0040","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10899-018-09815-y","article-title":"Pharmacological Treatments for Disordered Gambling: A Meta-analysis","volume":"35","author":"Goslar","year":"2019","journal-title":"J Gambl Stud"},{"key":"10.1016\/j.comppsych.2024.152566_bb0045","article-title":"Pharmacological interventions for the treatment of disordered and problem gambling","volume":"2022","author":"Dowling","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.comppsych.2024.152566_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/jrsm.1700","article-title":"Twenty years of network meta-analysis: Continuing controversies and recent developments","author":"Ades","year":"2024","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.comppsych.2024.152566_bb0055","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.comppsych.2024.152566_bb0060","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/aje\/kwab278","article-title":"Introducing the Treatment Hierarchy Question in Network Meta-Analysis","volume":"191","author":"Salanti","year":"2022","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.comppsych.2024.152566_bb0065","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.comppsych.2024.152566_bb0070","first-page":"5","article-title":"Network meta-analyses performed by contracting companies and commissioned by industry","author":"Schuit","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.comppsych.2024.152566_bb0075","author":"NICE"},{"key":"10.1016\/j.comppsych.2024.152566_bb0080","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.comppsych.2024.152566_bb0085","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152566_bb0090","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.comppsych.2024.152566_bb0095","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.comppsych.2024.152566_bb0100","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"White, Ian. Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata J"},{"key":"10.1016\/j.comppsych.2024.152566_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical Tools for Network Meta-Analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.comppsych.2024.152566_bb0110","article-title":"Various Coefficients of Interrater Reliability and Agreement - Package \u201cirr\u201d","author":"Gamer","year":"2022","journal-title":"CRAN Proj"},{"key":"10.1016\/j.comppsych.2024.152566_bb0115","doi-asserted-by":"crossref","first-page":"107127","DOI":"10.1016\/j.addbeh.2021.107127","article-title":"Intranasal as needed naloxone in the treatment of gambling disorder: A randomised controlled trial","volume":"125","author":"Alho","year":"2022","journal-title":"Addict Behav"},{"key":"10.1016\/j.comppsych.2024.152566_bb0120","first-page":"249","article-title":"Topiramate Combined with Cognitive Restructuring for the Treatment of Gambling Disorder: A Two-Center, Randomized","volume":"33","author":"de Brito","year":"2017","journal-title":"Double-Blind Clinical Trial J Gambl Stud"},{"key":"10.1016\/j.comppsych.2024.152566_bb0125","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.pbb.2007.12.025","article-title":"A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers","volume":"89","author":"Fong","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.comppsych.2024.152566_bb0130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.jcp.0000264985.25109.25","article-title":"Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study","volume":"27","author":"Black","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2024.152566_bb0135","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.jcp.0000186867.90289.ed","article-title":"Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study","volume":"25","author":"Dannon","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2024.152566_bb0140","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0006-3223(01)01079-4","article-title":"Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling","volume":"49","author":"Kim","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152566_bb0145","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0006-3223(00)00241-9","article-title":"A randomized double-blind fluvoxamine\/placebo crossover trial in pathologic gambling","volume":"47","author":"Hollander","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152566_bb0150","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.4088\/JCP.v63n0606","article-title":"A Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Paroxetine in the Treatment of Pathological Gambling","volume":"63","author":"Kim","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152566_bb0155","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000435876","article-title":"A Randomised, Double-Blind, Placebo-Controlled Trial of As-Needed Naltrexone in the Treatment of Pathological Gambling","volume":"22","author":"Kovanen","year":"2016","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.comppsych.2024.152566_bb0160","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4088\/JCP.v69n0314","article-title":"Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial","volume":"69","author":"McElroy","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152566_bb0165","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/15622975.2011.560964","article-title":"A double-blind, placebo-controlled trial of topiramate for pathological gambling","volume":"14","author":"Berlin","year":"2013","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152566_bb0170","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.yic.0000073881.93678.21","article-title":"Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial","volume":"18","author":"Grant","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2024.152566_bb0175","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/appi.ajp.163.2.303","article-title":"Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling","volume":"163","author":"Grant","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152566_bb0180","doi-asserted-by":"crossref","first-page":"783","DOI":"10.4088\/JCP.v69n0511","article-title":"A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges","volume":"69","author":"Grant","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152566_bb0185","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1192\/bjp.bp.110.078105","article-title":"Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study","volume":"197","author":"Grant","year":"2010","journal-title":"Br J Psychiatry"},{"issue":"2","key":"10.1016\/j.comppsych.2024.152566_bb0190","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/WNF.0000000000000585","article-title":"Milk Thistle (Silymarin) Treatment of Adults with Gambling Disorder: A Double-Blind, Placebo-Controlled Trial","volume":"47","author":"Grant","year":"2024","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.comppsych.2024.152566_bb0195","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.biopsych.2019.05.012","article-title":"The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence","volume":"86","author":"Clark","year":"2019","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152566_bb0200","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.2174\/1570159X15666170718144058","article-title":"Opioid Antagonists for Pharmacological Treatment of Gambling Disorder: Are they Relevant?","volume":"16","author":"Victorri-Vigneau","year":"2018","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.comppsych.2024.152566_bb0205","first-page":"872","article-title":"Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression","author":"Browne","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.comppsych.2024.152566_bb0210","series-title":"Meyler\u2019s Side Eff Drugs","first-page":"12","author":"Nalmefene","year":"2016"},{"key":"10.1016\/j.comppsych.2024.152566_bb0215","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1017\/S1461145713001284","article-title":"Nalmefene for the treatment of alcohol dependence: a current update","volume":"17","author":"Soyka","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.comppsych.2024.152566_bb0220","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1192\/apt.bp.107.004184","article-title":"Off-label prescribing in psychiatric practice","volume":"13","author":"Baldwin","year":"2007","journal-title":"Adv Psychiatr Treat"},{"key":"10.1016\/j.comppsych.2024.152566_bb0225","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.comppsych.2024.152566_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/neu.2024.52","article-title":"Placebo and nocebo effects in gambling disorder pharmacological trials: a meta-analysis","author":"Ioannidis","year":"2024","journal-title":"Acta Neuropsychiatr"},{"key":"10.1016\/j.comppsych.2024.152566_bb0235","doi-asserted-by":"crossref","first-page":"152410","DOI":"10.1016\/j.comppsych.2023.152410","article-title":"The UK Gambling White Paper: comments on implementation and timing","volume":"126","author":"Chamberlain","year":"2023","journal-title":"Compr Psychiatry"}],"container-title":["Comprehensive Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X24001172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X24001172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T17:26:05Z","timestamp":1736961965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010440X24001172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":47,"alternative-id":["S0010440X24001172"],"URL":"https:\/\/doi.org\/10.1016\/j.comppsych.2024.152566","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.10.20.23297314","asserted-by":"object"}]},"ISSN":["0010-440X"],"issn-type":[{"value":"0010-440X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological management of gambling disorder: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Comprehensive Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.comppsych.2024.152566","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152566"}}